logo

For the Inventor, By the Inventor

Tianjin, China

Zhongqi Shao

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignee: Cansino Biologics Inc.. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhongqi Shao. Retrieved from https://idiyas.com/inventor/zhongqi-shao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.2

ph-index = 1


Company Filing History:

goldMedal4 out of 5 
 
Cansino Biologics Inc.
 patents

Years Active: 2018-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 11795475 - Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof (2023-10-24),
2. 10716847 - fusion protein and construction method and use thereof (2020-07-21),
3. 10376572 - Immunogenic composition for preventing pneumococcal diseases and preparation method thereof (2019-08-13),
4. 10125175 - Method for enhancing immunogenicity of epitope peptide of HPV antigen, virus-like particle, and method for preparing HPV vaccine (2018-11-13),

Title: Innovations by Zhongqi Shao

Introduction

Zhongqi Shao is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the development of cell strains and fusion proteins. With a total of 4 patents, his work has the potential to impact vaccine production and immunogenicity.

Latest Patents

One of Zhongqi Shao's latest patents is a cell strain designed to reduce the production of replication competent adenovirus. This invention involves the HEK293.CS cell line, which is engineered to enhance safety in adenovirus production. By knocking out a specific gene fragment in HEK293 cells, this strain maintains growth and virus production capabilities while eliminating detectable replication competent adenovirus (RCA). This innovation is crucial for the mass culture of recombinant human type 5 adenovirus, particularly in the manufacturing of vaccines and antibodies.

Another notable patent involves a fusion protein and its construction method. This fusion protein combines a protein D and a Hin47 (Htra) protein, serving as a vehicle for polysaccharide-protein conjugate vaccines. This method significantly increases the immunogenicity of polysaccharide antigens, thereby enhancing vaccine efficacy.

Career Highlights

Zhongqi Shao is currently associated with CanSino Biologics Inc., a company known for its focus on innovative vaccine development. His work at CanSino has positioned him as a key player in the biotechnology sector, contributing to advancements that could revolutionize vaccine production.

Collaborations

Zhongqi has collaborated with notable colleagues such as Tao Zhu and Xuefeng Yu. Their combined expertise has fostered an environment of innovation and research excellence.

Conclusion

Zhongqi Shao's contributions to biotechnology through his patents and work at CanSino Biologics Inc. highlight his role as an influential inventor. His innovations in cell strains and fusion proteins are paving the way for safer and more effective vaccine production.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…